---
title: "mutn anticholinergics overactive uladder"
year: 2023
month: 08
journal: "American Family Physician"
volume: "108"
issue: "08"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2023-08-mbtn-anticholinergics-overactive-bladder.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# mutn anticholinergics overactive uladder

                                      Medicine by the Numbers
                                          A Collaboration of TheNNT.com and AFP

                  Oral Anticholinergics for Overactive
                          Bladder Symptoms
                                       Leah A. Stem, MD, MMed, and Sean P. Haley, MD, MPH

Details for This Review
Study Population:​Adults 18 years or older with a diagnosis                            THE NUMBERS
of symptomatic overactive bladder or detrusor overactivity
                                                                                       Benefits                            Harms

Efficacy End Points:​ Condition-specific quality of life;​                             1 in 7 was helped (patient          1 in 6 had dry mouth
patient perception of cure or improvement;​mean number                                 perception of cure or               1 in 111 had urinary retention
of urgency episodes per 24 hours;​mean number of micturi-                              improvement)
                                                                                                                           1 in 76 withdrew due to
tions per 24 hours                                                                     1 fewer episode of urgency          adverse events
                                                                                       per 24 hours on average

Harm End Points:​ Adverse events, including dry mouth
and urinary retention;​withdrawal from the trial due to
adverse events                                                                    (38 trials). Evidence of other bladder outlet obstruction was
                                                                                  a common criterion for exclusion.
Narrative:​ Overactive bladder describes a clinical syn-                             For primary outcomes, anticholinergic drugs improved
drome of urinary urgency with or without incontinence                             condition-specific quality of life compared with placebo
that may be related to spontaneous contraction of the                             (mean difference = −4.41;​95% CI, −5.28 to −3.54;​n = 6,804;​
detrusor smooth muscle. Overactive bladder causes both-                           low-quality evidence). Patients treated with anticholinergics
ersome symptoms in 29.8 million U.S. adults 40 years and                          perceived a greater sense of cure or improvement (rela-
older, with women being affected nearly twice as often as                         tive risk [RR] = 1.38;​95% CI, 1.15 to 1.66; absolute risk
men.1 Common treatment for overactive bladder includes                            difference [ARD] = 16%;​number needed to treat = 7;​n =
oral anticholinergics, which are thought to work by block-                        8,457;​ moderate-quality evidence). They also experienced
ing the muscarinic M 3 receptors of the bladder’s smooth                          reduced episodes of urinary urgency per 24 hours (mean
muscle, causing relaxation;​similar receptors are found                           difference = −0.85;​95% CI, −1.03 to −0.67;​n = 16,875;​
throughout the body. Common adverse events from oral                              moderate-quality evidence).2
anticholinergics include dry mouth, constipation, dyspep-                            Participants in the anticholinergic group were more likely
sia, abdominal pain, urinary retention, urinary tract infec-                      to withdraw from the trial due to adverse events (RR = 1.37;​
tion, dry eyes, blurred vision, headache, and dizziness. The                      95% CI, 1.21 to 1.56;​ARD = 1.3%;​number needed to harm
Cochrane review discussed here examines the benefits and                          [NNH] = 76;​n = 36,943). Compared with placebo, anticho-
harms of anticholinergic drugs compared with placebo for                          linergic drugs increased dry mouth (RR = 3.50;​95% CI, 3.26
the treatment of overactive bladder.2                                             to 3.75;​ARD = 16%;​NNH = 6;​n = 38,368) and increased uri-
   This Cochrane review included 104 multinational or                             nary retention (RR = 3.52;​95% CI, 2.04 to 6.08; ARD = 0.9%;​
single-country studies (n = 47,106) comparing placebo with                        NNH = 111;​n = 7,862). The quality of evidence for all harm
one of the following anticholiner-                                                                          outcomes was low.2
gic drugs at common clinical doses:​
darifenacin (Enablex), fesoterodine         The NNT Group Rating System                                           Caveats:​ This Cochrane review
(Toviaz), imidafenacin (not avail-                                                                                included a large number of stud-
able in the United States), oxybu-           Green    Benefits greater than harms                                 ies (104) examining nine differ-
tynin, propantheline (not available          Yellow Unclear benefits                                              ent anticholinergic agents for the
in the United States), propiverine                                                                                treatment of overactive bladder,
(not available in the United States),          Red    No benefits                                                 with significant variation in the
solifenacin (Vesicare), tolterodine,          Black   Harms greater than benefits                                 outcomes reported. The systematic
and trospium. Tolterodine was                                                                                     review showed statistically signif-
the most studied anticholinergic                                                                                  icant change in patient-reported

130  American
Downloaded  from Family   Physician
                 the American  Family Physician website at www.aafp.org/afp.            © 2023 American AcademyVolume
                                                                                 Copyright
                                                                   www.aafp.org/afp                                     of Family108,
                                                                                                                                  Physicians.
                                                                                                                                      Number  For2theAugust
                                                                                                                                                 ◆   private, non-
                                                                                                                                                              2023
commercial use of one individual user of the website. All other rights reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
                                                   MEDICINE BY THE NUMBERS


outcomes, but the effect sizes were modest. It is important             low, and a focus on specific adverse events during counsel-
to note that although anticholinergics were more effective              ing is warranted. Further studies can help stratify the risk
than placebo for all key measurements, the placebo effect on            of adverse events by age and with concurrent use of other
outcomes was also significant, indicating the complexity of             anticholinergic agents. We recommend discussing with
treating overactive bladder.                                            patients that using an oral anticholinergic for overactive
  A potential limitation to the practical implication of these          bladder is likely to help—but also may have some significant
data is the lack of stratification of adverse events by age.            adverse events.
As concerns for anticholinergic adverse events and burden               Copyright © 2023 MD Aware, LLC (theNNT.com). Used with
increase with age, it is unclear whether these agents dispro-           permission.
portionately cause withdrawal of treatment in older adults              This series is coordinated by Christopher W. Bunt, MD, AFP assis-
and, therefore, shift the balance from benefit to harm.                 tant medical editor, and the NNT Group.
                                                                        A collection of Medicine by the Numbers published in AFP is
Conclusion:​ The 2019 American Urological Association                   available at https://​w ww.aafp.org/afp/mbtn.
guidelines for treatment of nonneurogenic overactive                    Author disclosure:​No relevant financial relationships.
bladder in adults recommend behavior therapy as first-line
treatment, with anticholinergics as second-line treatment               References
or used in conjunction with behavior therapies. Extended-               1. Coyne KS, Sexton CC, Vats V, et al. National community prevalence of
                                                                           overactive bladder in the United States stratified by sex and age. Urol-
release formulations are recommended over immediate-                       ogy. 2011;​7 7(5):​1081-1087.
release formulations to reduce dry mouth.3                              2. Stoniute A, Madhuvrata P, Still M, et al. Oral anticholinergic drugs versus
  We assigned a color recommendation of green (benefits                    placebo or no treatment for managing overactive bladder syndrome in
                                                                           adults. Cochrane Database Syst Rev. 2023;​(5):​CD003781.
greater than harms) to this treatment. Anticholinergics
                                                                        3. Lightner DJ, Gomelsky A, Souter L, et al. Diagnosis and treatment of
improve quality of life and patients’ perception of cure and               overactive bladder (non-neurogenic) in adults:​AUA/SUFU guideline
improvement, with a small increased risk of some adverse                   amendment 2019. J Urol. 2019;​202(3):​558-563. ■
events. Overall withdrawal rates due to adverse events were




       AFP Case Studies
       On Demand, Focused Learning                                                                                                                  ON
                                                                                                                                                  DEMAND
       Eight sessions, in eight hours or less.                             Topics
       Access these on-demand sessions and                                       Cannabis
       stay up to date on key adult medicine                                     Contraception
       topics, whether you’re at home or on the                                  Fever of Unknown
       go.                                                                       Origin
       AFP Case Studies’ curated learning                                        Onychomycosis
       includes case scenarios, interactive                                      Oral Lesions
       learning activities, and downloadable PDFs,                               Orthostatic
       allowing you to hone in on timely adult                                   Hypotension
       medicine topics.                                                          Parathyroid Disorders
       Earn 10.50 AAFP Prescribed credits. AAFP members pay $295,                Recent-onset
       with reduced rates for AAFP member students, residents and new            Altered Mental Status
       physicians.



    aafp.org/cme/afpcasestudies                                                                        A
                                                                                                       AN EDITORIALLY INDEPENDENT, PEER
                                                                                                                                            F                       P                               ®



                                                                                                                                          EVIEWED JOURNAL OF THE AMERICAN ACADEMY OF FAMILY PHYSICIANS
